The results from the endoscopic pilot clinical trial of OXPzeroTM Naproxen confirm bioequivalence with standard naproxen and show encouraging signs of a reduction in the number of gastrointestinal erosions. Following the removal of subjects with prior gastric damage from the analysis, OXPzeroTM Naproxen demonstrated a c.38% reduction in the total number of erosions, a statistically significant result. Additional work is required to ensure OXPzeroTM Naproxen achieves its full potential and the pr ....
